Drugs / CMS121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05318040 | May → Dec 2022 | Alzheimer disease | Virogenics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMS121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05318040 ↗ |
| Modality | Small molecule | “CMS121 is a small molecule” NCT05318040 ↗ |
| Route | Oral | “delivered orally in capsule form” NCT05318040 ↗ |